« Levitra® Found Effective against ED in Hypertensive Men | Main | Avicena Group Inc.’s HD-02, Designated Orphan Drug for HD by USFDA »

Mar26
PXD101 and Velcade® (bortezomib), Into Phase Ib/II Clinical Trial for Multiple Myeloma (MM)
velcade.jpg

Multiple myeloma is a deadly form of blood cancer, characterized by excessive numbers of abnormal plasma cells in the bone marrow and the overproduction of abnormal immunoglobulins.

 

Recently, CuraGen Corporation and TopoTarget A/S initiated the patient dosing in a Phase Ib/II proof-of-concept trial to evaluate PXD101, a small molecule histone deacetylase (HDAC) inhibitor, in combination with Velcade® (bortezomib) for the treatment of relapsed, refractory multiple myeloma (MM).

The goal of the Phase Ib portion of this trial is to establish the maximum tolerated dose (MTD) of PXD101 in combination with Velcade® in up to 30 patients who have failed at least two prior lines of therapy for multiple myeloma.

Following determination of the MTD, the study will enter Phase II and enroll up to 15 additional patients with relapsed, refractory multiple myeloma who have failed at least one prior therapy.

The Phase II portion of the study will further evaluate the safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity of PXD101 in combination with Velcade®. Patients will be enrolled at multiple sites in the United States.

Read Curagen’s press release.

Photo Credit: Millennium Products

related entries


1 Comments/Trackbacks




» CuraGen and TopoTarget Commenced Phase I/II Trial of PXD101 for Hepatocellular Cancer (Liver Cancer) from ThePharmVoice
CuraGen Corporation and TopoTarget A/S commenced the patient dosing of PXD101 (a small molecule histone deacetylase (HDAC) inhibitor) in a Phase I/II clinical trial evaluating the safety and potential efficacy of the product for the treatment of inoper... [Read More]

submit a trackback

TrackBack URL for this entry:

post a comment

Name, Email Address, and URL are not required fields.





Comment Preview

« Levitra® Found Effective against ED in Hypertensive Men | Main | Avicena Group Inc.’s HD-02, Designated Orphan Drug for HD by USFDA »

Advertise

Watch the Digital Health Revolution


sponsored ads



subscribe


Prefer Email?
Subscribe below-

Enter your Email:


Powered by FeedBlitz What's this?

Current News

Support This Blog

top blogs

business social media

Use these fast growing business social media sites to promote your business, feature your products, spotlight your business leaders, create links, and drive traffic back to your company site, all for free!

BIZZlogos - Add your logo - free link to your site
BIZZphotos - Add photos of your products and people
BIZZprofiles - Submit your profile and build your online visibility
BIZZspotlight - Spotlight your business with free links
BIZZvideos - Videos about businesses, products and business people.
BIZZbites - "Digg" for Business - Submit your articles and posts

Know More Media - Health Care / Pharmaceutical / Fitness

know more media network

View Network Map

Network Feed List (OPML)

Know More Media Network
Feed


we support unitus

PRWeb

Influencer



PharmaGazette is a member of the Know More Media network of business related blogs.

Here are some current headlines from some of our business publications:

ProductivityGoal

CallCenterScript

AdHurl

TheBizofKnowledge

LandingTheDeal

CustomersAreAlways

HealthCareVox

BrainBasedBusiness

TheInsurancePolicy

MarketingBlurb